Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Utah • HR+ • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
If neoadjuvant therapy is indicated for luminal A breast cancer, when do you decide to use chemotherapy versus endocrine therapy?
Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?
Answer from: Medical Oncologist at Community Practice
My practice is to perform recurrence risk assay on biopsy specimen and decide on the choice of neoadjuvant therapy (chemo vs anti estrogen). A clear indication for chemotherapy would not require a recurrence risk assay.
Sign in or Register to read more